Prostate Cancer Genetic Risk Evaluation and Screening Study

  • Recruiting
  • Observational
  • Diagnostic Test
  • Massachusetts General Hospital
  • 35 - 74 Years


Study Purpose

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Intervention

Diagnostic Test : Prostate cancer screening


Eligibility Requirements

info icon Men 35-74 years old

info icon No known diagnosis of prostate cancer

info icon Life expectancy \>10 years

info icon Meet cohort A, B, or C criteria

info icon Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)

info icon Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing

info icon Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry

info icon Minimum age: 35

info icon Prior diagnosis or treatment of prostate cancer

info icon Inability to undergo prostate MRI

info icon Inability to receive MRI contrast agent

Recruiting status

Recruiting

Estimated enrollment

400

 
Study start date

Feb 12, 2020

Study end date

Dec 31, 2040

Last updated

Mar 23, 2025

Primary purpose

N/A

Design

Observational

Intervention

Diagnostic Test

Study phase

N/A

Allocation

N/A

 

Sponsor:

Massachusetts General Hospital

Collaborator:

N/A

Investigator:

Keyan Salari, MD, PhD

NCT05129605

Clinic Location Investigator Distance RECRUITING STATUS Contact